Peptides

This section covers substances ranging from FDA-approved prescription medications to unregulated "research chemicals." Nothing here is a recommendation to use any of these. Some legally require a prescription and medical supervision; others have little to no human safety data at all. Talk to a doctor before considering any of them — see our Terms of Use for our full medical disclaimer.

"Peptides" is a loose umbrella term applied to an enormous range of substances with very different legal, regulatory, and evidence profiles — everything from long-approved prescription drugs to compounds sold online explicitly labeled "not for human consumption." Treating all of that as one category would be misleading, so every page below is sorted into one of three tiers based on its actual regulatory status and evidence base, stated clearly near the top of that page before anything else.

Real, regulated drugs with actual clinical trial data behind their approved uses — available only with a prescription. Pages in this tier can describe approved uses and standard prescribed dosing, since that's public medical information about a regulated drug, not usage guidance for an underground substance.

Some legitimate research or medical history exists, but these are not FDA-approved for general or fitness use today, and most have limited or no completed human clinical trial data — some were approved decades ago for a narrow medical use and are no longer marketed; others exist mainly in animal studies and a small number of human pilot studies. We describe the mechanism and the real research. We do not provide dosing, administration, or usage guidance for anything in this tier.

Substances sold online labeled "not for human consumption" specifically to avoid FDA drug regulation. Little to no human safety data exists. We cover what these are and what, if anything, is actually known about them — not how to use them.

Effective April 22, 2026, the FDA removed a group of peptides — including BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, GHK-Cu (injectable), Melanotan II, PEG-MGF, LL-37, Emideltide (DSIP), and dihexa acetate — from its Category 2 "significant safety risk" bulk drug substances list. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six of those substances (BPC-157, TB-500, KPV, Semax, Epitalon, and MOTS-c) for formal addition to the list compounding pharmacies are permitted to use; Emideltide (DSIP) was not recommended. GHK-Cu (injectable), Melanotan II, LL-37, PEG-MGF, and dihexa were not on that July docket — the FDA has indicated a separate advisory meeting will address them, expected before the end of February 2027.

None of this is FDA drug approval. A favorable advisory-committee vote is a recommendation, not a rule change — compounding pharmacies cannot legally prepare these substances under Section 503A until the FDA completes formal rulemaking, typically an 8–24 month process. This action only concerns whether a compounding pharmacy may eventually be allowed to prepare a substance; it does not establish FDA approval, a validated medical indication, standard dosing, or an established benefit-risk profile for any of these peptides. Those still require full Phase 1–3 clinical review, which none of them has completed. Melanotan II in particular carries documented safety concerns (see its page) that make near-term reclassification unlikely regardless of its Category 2 paperwork status.

Separately, CJC-1295, Ipamorelin, AOD-9604, and Thymosin Alpha-1 went through an earlier, unrelated FDA review in 2024 — nominations withdrawn, referred to the same advisory committee, which then voted against recommending most of them for the compounding-permitted list. That's a different and generally less favorable outcome than the substances above, and it isn't part of the 2026 action.

This is a fast-moving area and our summary here may lag the FDA's own updates — verify current status directly with FDA.gov before making any decision based on it.